



Figure 5: (a) Heatmap showing unsupervised clustering of all glioblastoma samples based on nanopore sequencing of the *MGMT* promoter ($n = 103$). Kaplan-Meier patient survival curves based on (b) MGMT pyro kit classification or (c) hierarchical clustering according to nanopore sequencing in Figure 5a. Dotted lines represent group median survival (Pyrosequencing-methylated = 22.5 months, Pyrosequencing-unmethylated = 17.9 months, Nanopore-Cluster1 = 20.9 months, Nanopore Cluster2 = 23.0 months).